An FDA Form 483 lists the investigator’s observations at the end of an inspection. It is not a final agency decision, but how a company responds strongly shapes what happens next. In my experience leading remediation programs in medical device manufacturing, the first 30 days decide whether the response is credible and whether the business keeps shipping.
Days 1–3: triage and ownership
- Name one accountable executive and one program lead. Remediation without a single owner drifts.
- Assign each observation a technical owner and a first assessment date.
- Quantify business exposure immediately: which SKUs, how much revenue and which customers are affected if product is held.
- Decide what, if anything, must be contained now rather than after the response.
Days 4–15: write a response you can keep
FDA generally considers responses received within 15 business days when deciding whether further action is needed. A strong response addresses each observation with root cause, correction, corrective action, systemic review beyond the specific example, and dates.
The most common mistake is overpromising. Dates written under pressure become commitments the agency will check. Build the response from a real plan, not the other way around.
Days 15–30: turn the response into a program
- Structure pathways. Separate fast recovery of held product from the durable fix and from longer-term resilience, so the business isn’t waiting on the slowest path.
- Set the rhythm. Daily management for the working team, a weekly steering committee for decisions, and concise reporting to the CEO.
- Line up outside capacity early. External labs, contract sterilizers and consultants have lead times of their own.
- Report in revenue as well as milestones. Leaders fund what they can see.
- Plan follow-up updates to the agency so progress is visible.
What good looks like at day 30
A submitted response you are confident you can deliver, a funded plan with owners and dates for every observation, a clear view of revenue at risk and the recovery path for each SKU, and a governance rhythm that is already running.
If you are facing a 483 or a product hold, I lead remediation programs for medical device manufacturers. See how a three-pathway sterilization remediation recovered $15M+ in revenue, or get in touch.
